WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report “Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018”
Non-ulcer dyspepsia is a term used to describe signs and symptoms of indigestion that have no obvious cause. Non-ulcer dyspepsia is also called functional dyspepsia or non-ulcer stomach pain. Signs and symptoms include burning sensation or discomfort in upper abdomen or lower chest, sometimes relieved by food or antacids, bloating, belching and nausea.
The predisposing factors include consuming excessive amounts of caffeine or alcohol, smoking and taking certain medications, especially certain over-the-counter pain relievers, such as aspirin and ibuprofen (advil, motrin, others), which can cause stomach problems. Treatment includes medications to reduce acid production, antibiotics and low-dose antidepressants.
Click here for sample report @ https://www.wiseguyreports.com/sample-request/2593466-gastrointestinal-stromal-tumor-gist-pipeline-review-h2-2017
AB Science SA
Advanced Accelerator Applications SA
Ariad Pharmaceuticals Inc
Arog Pharmaceuticals Inc
Array BioPharma Inc
Ascentage Pharma Group Corp Ltd
Astex Pharmaceuticals Inc
Blueprint Medicines Corp
Boston Biomedical Inc
Calithera Biosciences Inc
Celldex Therapeutics Inc
Chipscreen Biosciences Ltd
Deciphera Pharmaceuticals LLC
Eli Lilly and Co
- Hoffmann-La Roche Ltd
Hanmi Pharmaceuticals Co Ltd
Horizon Pharma Plc
Jiangsu Hengrui Medicine Co Ltd
Loxo Oncology Inc
Merck & Co Inc
Natco Pharma Ltd
Nerviano Medical Sciences Srl
Pharma Mar SA
Rhizen Pharmaceuticals SA
Taiho Pharmaceutical Co Ltd
Gastrointestinal Stromal Tumor (GIST) Industry Major Highlights:
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (GIST) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gastrointestinal Stromal Tumor (GIST) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.
Gastrointestinal Stromal Tumor (GIST) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Competitive Analysis for Gastrointestinal Stromal Tumor (GIST)
Key players are making innovative developments in Gastrointestinal Stromal Tumor (GIST) industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector.
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2593466-gastrointestinal-stromal-tumor-gist-pipeline-review-h2-2017
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
P: +44 208 133 9349
M: +1 646 845 9349